THOMSON TODD S

SEC source: 0001683168-26-004257 · ownership.xml · derivative · entry 1

THOMSON TODD S · CIK 0001225707 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2036-05-21

F2 · kind: Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of Kairos Venture Investments, LLC ("KVI"), and serves on the board of directors (the "Board") of Actuate Therapeutics, Inc. ("Actuate"). Mr. Thomson has advised Actuate that he serves on the Board as a representative of certain funds managed and controlled by KVI (the "Kairos Funds") and because Mr. Thomson serves on the Board as a representative of the Kairos Funds, certain of the Kairos Funds have a right to an economic interest in the securities of Actuate granted to Mr. Thomson in respect of his Board position and such Kairos Funds are entitled to an indirect pecuniary interest in such securities, including the Stock Options reported on this Form 4.

F1 · derivative.exercise_date: Options will vest in full on the anniversary of the grant date.

F2 · ownership.direct: Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of Kairos Venture Investments, LLC ("KVI"), and serves on the board of directors (the "Board") of Actuate Therapeutics, Inc. ("Actuate"). Mr. Thomson has advised Actuate that he serves on the Board as a representative of certain funds managed and controlled by KVI (the "Kairos Funds") and because Mr. Thomson serves on the Board as a representative of the Kairos Funds, certain of the Kairos Funds have a right to an economic interest in the securities of Actuate granted to Mr. Thomson in respect of his Board position and such Kairos Funds are entitled to an indirect pecuniary interest in such securities, including the Stock Options reported on this Form 4.

SEC source: 0001011438-26-000005 · form4.xml · nonDerivative · entry 1

THOMSON TODD S · CIK 0001225707 · Director · 10% owner

Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Kairos Venture Partners II, L.P.

Disclosed balance after: 904,795

F1 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI.

F2 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purpose.

SEC source: 0001683168-25-004001 · ownership.xml · derivative · entry 1

THOMSON TODD S · CIK 0001225707 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2035-05-22

F2 · kind: Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of Kairos Venture Investments, LLC ("KVI"), and serves on the board of directors (the "Board") of Actuate Therapeutics, Inc. ("Actuate"). Mr. Thomson has advised Actuate that he serves on the Board as a representative of certain funds managed and controlled by KVI (the "Kairos Funds") and because Mr. Thomson serves on the Board as a representative of the Kairos Funds, certain of the Kairos Funds have a right to an economic interest in the securities of Actuate granted to Mr. Thomson in respect of his Board position and such Kairos Funds are entitled to an indirect pecuniary interest in such securities, including the Stock Options reported on this Form 4.

F1 · derivative.exercise_date: Options will vest in full on the anniversary of the grant date.

F2 · ownership.direct: Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of Kairos Venture Investments, LLC ("KVI"), and serves on the board of directors (the "Board") of Actuate Therapeutics, Inc. ("Actuate"). Mr. Thomson has advised Actuate that he serves on the Board as a representative of certain funds managed and controlled by KVI (the "Kairos Funds") and because Mr. Thomson serves on the Board as a representative of the Kairos Funds, certain of the Kairos Funds have a right to an economic interest in the securities of Actuate granted to Mr. Thomson in respect of his Board position and such Kairos Funds are entitled to an indirect pecuniary interest in such securities, including the Stock Options reported on this Form 4.

SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · derivative · entry 21

THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner

Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner

Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner

Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner

Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By KVP II, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 28,464 shares

Expires not disclosed

F8 · derivative.exercise_price: On August 14, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 28,464 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 18,750 of the warrant shares to pay the exercise price and issuing to Kairos Venture Partners II, L.P. the remaining 9,714 shares.

F8 · price: On August 14, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 28,464 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 18,750 of the warrant shares to pay the exercise price and issuing to Kairos Venture Partners II, L.P. the remaining 9,714 shares.

F8 · derivative.exercise_date: On August 14, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 28,464 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 18,750 of the warrant shares to pay the exercise price and issuing to Kairos Venture Partners II, L.P. the remaining 9,714 shares.

F8 · derivative.expiration_date: On August 14, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 28,464 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 18,750 of the warrant shares to pay the exercise price and issuing to Kairos Venture Partners II, L.P. the remaining 9,714 shares.

F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI.

F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase.

SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · derivative · entry 20

THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner

Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner

Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner

Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner

Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Kairos SPV Fund, LLC

Disclosed balance after: 0

Underlying: Common Stock · 49,984 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_price: The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F7 · price: The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F7 · derivative.exercise_date: The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F7 · derivative.expiration_date: The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI.

F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase.

SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · derivative · entry 19

THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner

Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner

Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner

Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner

Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Kairos-Actuate SPV, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 24,138 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_price: The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F7 · price: The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F7 · derivative.exercise_date: The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F7 · derivative.expiration_date: The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI.

F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase.

SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · derivative · entry 18

THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner

Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner

Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner

Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner

Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Kairos SPV Fund, LLC

Disclosed balance after: 0

Underlying: Common Stock · 132,908 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F6 · price: The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F6 · derivative.exercise_date: The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F6 · derivative.expiration_date: The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI.

F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase.

SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · derivative · entry 17

THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner

Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner

Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner

Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner

Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Kairos-Actuate SPV, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 230,597 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F6 · price: The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F6 · derivative.exercise_date: The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F6 · derivative.expiration_date: The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI.

F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase.

SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · derivative · entry 16

THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner

Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner

Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner

Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner

Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Kairos SPV Fund, LLC

Disclosed balance after: 0

Underlying: Common Stock · 138,889 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F5 · price: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F5 · derivative.exercise_date: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F5 · derivative.expiration_date: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI.

F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase.

SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · derivative · entry 15

THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner

Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner

Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner

Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner

Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By KVOI, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 146,870 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F5 · price: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F5 · derivative.exercise_date: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F5 · derivative.expiration_date: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI.

F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase.

SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · derivative · entry 14

THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner

Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner

Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner

Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner

Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By KVP II, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 69,445 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F5 · price: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F5 · derivative.exercise_date: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F5 · derivative.expiration_date: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI.

F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase.

SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · derivative · entry 13

THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner

Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner

Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner

Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner

Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By KVOI, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 726,163 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: The shares of Series B-2 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F4 · price: The shares of Series B-2 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F4 · derivative.exercise_date: The shares of Series B-2 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F4 · derivative.expiration_date: The shares of Series B-2 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI.

F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase.

SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · derivative · entry 12

THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner

Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner

Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner

Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner

Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By KVP II, L.P.

Disclosed balance after: 0

Underlying: Common Stock · 1,058,318 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The shares of Series B-1 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F1 · price: The shares of Series B-1 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F1 · derivative.exercise_date: The shares of Series B-1 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F1 · derivative.expiration_date: The shares of Series B-1 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI.

F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase.

SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · nonDerivative · entry 11

THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner

Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner

Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner

Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner

Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By KVP II, L.P.

Disclosed balance after: 1,184,795

F8 · kind: On August 14, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 28,464 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 18,750 of the warrant shares to pay the exercise price and issuing to Kairos Venture Partners II, L.P. the remaining 9,714 shares.

F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI.

F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase.

SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · nonDerivative · entry 10

THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner

Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner

Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner

Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner

Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By KVP II, L.P.

Disclosed balance after: 1,203,545

F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI.

F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase.

SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · nonDerivative · entry 9

THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner

Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner

Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner

Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner

Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Kairos SPV Fund, LLC

Disclosed balance after: 321,781

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · price: The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI.

F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase.

SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · nonDerivative · entry 8

THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner

Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner

Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner

Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner

Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Kairos-Actuate SPV, L.P.

Disclosed balance after: 254,735

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · price: The shares of Series C Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI.

F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase.

SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · nonDerivative · entry 7

THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner

Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner

Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner

Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner

Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Kairos SPV Fund, LLC

Disclosed balance after: 271,797

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · price: The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI.

F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase.

SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · nonDerivative · entry 6

THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner

Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner

Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner

Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner

Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Kairos-Actuate SPV, L.P.

Disclosed balance after: 230,597

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · price: The shares of Series B-4 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI.

F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase.

SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · nonDerivative · entry 5

THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner

Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner

Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner

Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner

Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Kairos SPV Fund, LLC

Disclosed balance after: 138,889

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI.

F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase.

SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · nonDerivative · entry 4

THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner

Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner

Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner

Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner

Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By KVOI, L.P.

Disclosed balance after: 873,033

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI.

F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase.

SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · nonDerivative · entry 3

THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner

Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner

Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner

Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner

Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By KVP II, L.P.

Disclosed balance after: 1,175,081

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: The shares of Series B-3 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI.

F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase.

SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · nonDerivative · entry 2

THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner

Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner

Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner

Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner

Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By KVOI, L.P.

Disclosed balance after: 726,163

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: The shares of Series B-2 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI.

F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase.

SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · nonDerivative · entry 1

THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner

Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner

Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner

Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner

Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By KVP II, L.P.

Disclosed balance after: 1,105,636

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares of Series B-1 Redeemable Convertible Preferred Stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO and had no expiration date.

F2 · ownership.nature: The securities of Actuate Therapeutics, Inc. ("Actuate") that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the "Kairos Funds"). The Kairos Funds are managed and controlled by Kairos Venture Investments, LLC ("KVI"), subject to the Limited Partnership Agreements in place for each Kairos Fund. Todd Thomson serves as Chief Financial Officer/Chief Operating Officer of KVI and is a director on the board of directors of Actuate. James Demetriades is the Chief Executive Officer of KVI.

F3 · ownership.nature: Each of KVI, Mr. Thomson and Mr. Demetriades may be deemed to indirectly beneficially own the securities of Actuate held directly by the Kairos Funds. Each of KVI, Mr. Thomson and Mr. Demetriades disclaims beneficial ownership of the securities of Actuate held directly by the Kairos Funds except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that any of KVI, Mr. Thomson or Mr. Demetriades is the beneficial owner of such securities for purposes of Section 16 or any other purchase.

SEC source: 0001104659-24-090619 · tm2421960-1_4seq1.xml · derivative · entry 22

THOMSON TODD S · CIK 0001225707 · Director · 16.4% Owner

Kairos SPV Fund LLC · CIK 0001788046 · Director · 2% Owner

Kairos Venture Opportunities I, L.P. · CIK 0001772438 · Director · 5.3% Owner

Kairos Venture Partners II, L.P. · CIK 0001696711 · Director · 7.6% Owner

Kairos-Actuate SPV, L.P. · CIK 0001835962 · Director · 1.5% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2034-08-12

F9 · derivative.exercise_date: 15,000 stock options granted upon the effectiveness of the registration statement for the issuer's initial public offering on August 12, 2024, which vest in full on the first anniversary of the grant date.

SEC source: 0001213900-21-000679 · ownership.xml · nonDerivative · entry 1

THOMSON TODD S · CIK 0001225707 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,000

F1 · shares: These shares were issued as a restricted stock unit grant to the Reporting Person by the issuer under the issuer's 2016 Non-Employee Director Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on January 4, 2022.

SEC source: 0001213900-20-000555 · ownership.xml · nonDerivative · entry 1

THOMSON TODD S · CIK 0001225707 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

F1 · shares: These shares were issued as a restricted stock unit grant to the reporting person by the issuer under the issuer's 2016 Non-Employee Director Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on January 06, 2021.

SEC source: 0001213900-19-001191 · ownership.xml · nonDerivative · entry 1

THOMSON TODD S · CIK 0001225707 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

F1 · shares: These shares were issued as a restricted stock unit grant to the reporting person by the issuer under the issuer's 2016 Non-Employee Director Equity Incentive Plan. The restricted stock units vest in four equal annual installments beginning on January 22, 2020.

SEC source: 0001181431-06-071435 · rrd140130.xml · derivative · entry 26

THOMSON TODD S · CIK 0001225707 · Chair/CEO Global Wealth Mgt.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,363

Underlying: Common Stock · 25,363 shares

Expires 2008-07-22

SEC source: 0001181431-06-071435 · rrd140130.xml · derivative · entry 25

THOMSON TODD S · CIK 0001225707 · Chair/CEO Global Wealth Mgt.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,281

Underlying: Common Stock · 8,281 shares

Expires 2008-11-02

SEC source: 0001181431-06-071435 · rrd140130.xml · derivative · entry 24

THOMSON TODD S · CIK 0001225707 · Chair/CEO Global Wealth Mgt.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,659

Underlying: Common Stock · 25,659 shares

Expires 2008-11-02

SEC source: 0001181431-06-071435 · rrd140130.xml · derivative · entry 23

THOMSON TODD S · CIK 0001225707 · Chair/CEO Global Wealth Mgt.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,283

Underlying: Common Stock · 2,283 shares

Expires 2008-11-02

SEC source: 0001181431-06-071435 · rrd140130.xml · derivative · entry 22

THOMSON TODD S · CIK 0001225707 · Chair/CEO Global Wealth Mgt.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,148

Underlying: Common Stock · 18,148 shares

Expires 2008-07-22

SEC source: 0001181431-06-071435 · rrd140130.xml · derivative · entry 21

THOMSON TODD S · CIK 0001225707 · Chair/CEO Global Wealth Mgt.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,184 shares

Expires 2008-11-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001181431-06-071435 · rrd140130.xml · derivative · entry 20

THOMSON TODD S · CIK 0001225707 · Chair/CEO Global Wealth Mgt.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 28,460 shares

Expires 2008-11-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001181431-06-071435 · rrd140130.xml · derivative · entry 19

THOMSON TODD S · CIK 0001225707 · Chair/CEO Global Wealth Mgt.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,532 shares

Expires 2008-11-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001181431-06-071435 · rrd140130.xml · derivative · entry 18

THOMSON TODD S · CIK 0001225707 · Chair/CEO Global Wealth Mgt.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 28,131 shares

Expires 2008-07-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001181431-06-071435 · rrd140130.xml · derivative · entry 17

THOMSON TODD S · CIK 0001225707 · Chair/CEO Global Wealth Mgt.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,195 shares

Expires 2008-07-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001181431-06-071435 · rrd140130.xml · nonDerivative · entry 15

THOMSON TODD S · CIK 0001225707 · Chair/CEO Global Wealth Mgt.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 489,440.9

SEC source: 0001181431-06-071435 · rrd140130.xml · nonDerivative · entry 14

THOMSON TODD S · CIK 0001225707 · Chair/CEO Global Wealth Mgt.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 490,146.9

SEC source: 0001181431-06-071435 · rrd140130.xml · nonDerivative · entry 13

THOMSON TODD S · CIK 0001225707 · Chair/CEO Global Wealth Mgt.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 497,721.9

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001181431-06-071435 · rrd140130.xml · nonDerivative · entry 12

THOMSON TODD S · CIK 0001225707 · Chair/CEO Global Wealth Mgt.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 488,537.9

SEC source: 0001181431-06-071435 · rrd140130.xml · nonDerivative · entry 11

THOMSON TODD S · CIK 0001225707 · Chair/CEO Global Wealth Mgt.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 490,721.9

SEC source: 0001181431-06-071435 · rrd140130.xml · nonDerivative · entry 10

THOMSON TODD S · CIK 0001225707 · Chair/CEO Global Wealth Mgt.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 514,196.9

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001181431-06-071435 · rrd140130.xml · nonDerivative · entry 9

THOMSON TODD S · CIK 0001225707 · Chair/CEO Global Wealth Mgt.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 485,736.9

SEC source: 0001181431-06-071435 · rrd140130.xml · nonDerivative · entry 8

THOMSON TODD S · CIK 0001225707 · Chair/CEO Global Wealth Mgt.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 485,931.9

SEC source: 0001181431-06-071435 · rrd140130.xml · nonDerivative · entry 7

THOMSON TODD S · CIK 0001225707 · Chair/CEO Global Wealth Mgt.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 488,019.9

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001181431-06-071435 · rrd140130.xml · nonDerivative · entry 6

THOMSON TODD S · CIK 0001225707 · Chair/CEO Global Wealth Mgt.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 485,487.9

SEC source: 0001181431-06-071435 · rrd140130.xml · nonDerivative · entry 5

THOMSON TODD S · CIK 0001225707 · Chair/CEO Global Wealth Mgt.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 487,646.9

SEC source: 0001181431-06-071435 · rrd140130.xml · nonDerivative · entry 4

THOMSON TODD S · CIK 0001225707 · Chair/CEO Global Wealth Mgt.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 510,850.9

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.